Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2000-03-17
2004-10-12
Cook, Rebecca (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
active
06803387
ABSTRACT:
This invention relates to a method of treating neuropathic pain or fibromyalgia.
According to the present invention there is provided a method of treating neuropathic pain or fibromyalgia, in which a therapeutically effective amount of a compound of formula I
including enantiomers and pharmaceutically acceptable salts thereof, in which R
1
and R
2
are independently H or methyl, is administered in conjunction with a pharmaceutically acceptable diluent or carrier to a human in need thereof.
Neuropathic pain which may advantageously be treated with a compound of formula I includes pain associated with diabetes mellitus, shingles, nerve injury and varied peripheral neuropathies.
A preferred compound of formula I is N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine or a salt thereof, for example the hydrochloride salt. A preferred form of this hydrochloride is its monohydrate.
The preparation and use of compounds of formula I, such as N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine, N-{1-[1-(4-chlorophenyl)-cyclobutyl]-3-methylbutyl}-N-methylamine, and 1-[1-(4-chlorophenyl)-cyclobutyl]-3-methylbutylamine and salts thereof, in the treatment of depression is described in British Patent Specification 2098602 and U.S. Pat. No. 4,522,828. The use of compounds of formula I such as N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine and salts thereof in the treatment of Parkinson's disease is described in published PCT application WO 88/06444. The use of N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine and salts thereof in the treatment of cerebral function disorders is described in U.S. Pat. No. 4,939,175. The use of N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine hydrochloride in the treatment of obesity is described published PCT application WO90/06110. A particularly preferred form of this compound is N,N-dimethyl-1-[1-(chlorophenyl)cyclobutyl]-3-methylbutylamine hydrochloride monohydrate (sibutramine hydrochloride) which is described in European Patent Number 230742. The use of N,N-dimethyl-1-[1-(4-chlorophenyl) cyclobutyl]-3-methylbutylamine and salts thereof for improving the glucose tolerance of humans having Impaired Glucose Tolerance or Non-Insulin Dependent Diabetes Mellitus is described in published PCT application W095/20949.
It will be appreciated by those skilled in the art that compounds of formula I contain a chiral centre. When a compound of formula I contains a single chiral centre it may exist in two enantiomeric forms. The present invention includes the use of the individual enantiomers and mixtures of the enantiomers. The enantiomers may be resolved by methods known to those skilled in the art, for example by formation of diastereoisomeric salts or complexes which may be separated, for example, by crystallisation; via formation of diastereoisomeric derivatives which may be separated, for example, by crystallisation, gas-liquid or liquid chromatography; selective reaction of one enantiomer with an enantiomer-specific reagent, for example enzymatic oxidation or reduction, followed by separation of the modified and unmodified enantiomers; or gas-liquid or liquid chromatography in a chiral environment, for example on a chiral support, for example silica with a bound chiral ligand or in the presence of a chiral solvent. It will be appreciated that where the desired enantiomer is converted into another chemical entity by one of the separation procedures described above, a further step is required to liberate the desired enantiomeric form. Alternatively, specific enantiomers may be synthesised by asymmetric synthesis using optically active reagents, substrates, catalysts or solvents, or by converting one enantiomer to the other by asymmetric transformation.
Preferred compounds of formula I are N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine, N-{1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N-methylamine, and 1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine including racemates, individual enantiomers and mixtures thereof, and pharmaceutically acceptable salts thereof.
The individual enantiomers can be prepared by enantioselective synthesis from optically active precursors, or by resolving the racemic compound which can be prepared as described above. Enantiomers of secondary amines of the formula I can also be prepared by preparing the racemate of the corresponding primary amine, resolving the latter into the individual enantiomers, and then converting the optically pure primary amine enantiomer into the required secondary amine by methods described in British Patent Specification 2098602.
REFERENCES:
patent: 4522828 (1985-11-01), Jeffery et al.
patent: 4939175 (1990-03-01), Ukai et al.
patent: 5166207 (1992-11-01), Smith
patent: 5436272 (1995-07-01), Scheinbaum
patent: 5877188 (1999-03-01), McCullough et al.
patent: 6004927 (1999-12-01), Benet et al.
patent: 6323242 (2001-11-01), Mueller
patent: 230742 (1987-08-01), None
patent: 88/06444 (1988-09-01), None
patent: 90/06110 (1990-06-01), None
patent: 95/20949 (1995-08-01), None
patent: 98/41528 (1998-09-01), None
EMBASE AN 1999182621, Bloomgarden, Diabetes Care, 22/6, 989-995, abstract, 1999.*
A. Hsu, et al., “Clinical pharmacokinetics and interactions with other anti-HIV agents”,Clin. Pharmacokinet. 35(4), 275-291 (1988).
A. Adeyoyin, et al., “Chloroquine modulation of specific metabolizing enzymes activities: investigation with selective five drug cocktail”,Br. J. Clin. Pharmacol., 46, 215-219 (1998).
A. A. B. Joos et al., “Dose-dependent pharmacokinetic interaction of clozapine and paroxetine in an extensive metabolizer”,Pharmacopsychiat., 30, 266-270 (1997).
G. Lurcott, “The effects of the genetic absence and inhibition of CYP2D6 on the metabolism of codeine and its derivatives, hydrocodone and oxycodone,”Anesth. Prog., 45, 154-156 1999.
Chong Edward
Mendel Carl M.
Seaton Timothy B.
Weinstein Steve P.
Abbott & GmbH & Co. KG
Conway John D.
Cook Rebecca
O'Brien Gayla B.
LandOfFree
Treatment of neuropathic pain or fibromyalgia does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of neuropathic pain or fibromyalgia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of neuropathic pain or fibromyalgia will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3312586